Background The progressive loss of renal function in chronic kidney disease (CKD) necessitates the eventual use of dialysis. Renal Osteodystrophy (ROD) is a serious complication of CKD with diverse and non-specific manifestations. Serum biochemical markers such as Parathyroid hormone (PTH) are used worldwide to monitor bone changes in patients on haemodialysis although bone biopsy has remained the gold standard. The use of PTH as a marker for bone changes has however been associated with a lot of controversies linked to its measurement and interpretation. Recommendations from several studies have been proposed on how to improve its clinical robustness in monitoring bone changes of patients on haemodialysis. Evaluation of these recommendati...
Objective: Many people who have severe chronic kidney disease (CKD) will eventually develop kidney f...
Background: New bone metabolic markers have become available clinically for evaluating chronic kidne...
BACKGROUND: The management of chronic kidney disease-mineral and bone disorder requires the assessm...
The non-invasive diagnosis of bone turnover in patients with chronic kidney disease (CKD) remains di...
Background and objectives: Clinical management of mineral bone disorder in patients with kidney fail...
Background: Mineral bone disease (MBD) is a systemic disorder of mineral and bone metabolism due to ...
Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders ...
Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). Intern...
Background and objective: Despite the high mortality and morbidity associated with abnormalities in ...
Controversies surrounding the use of Parathyroid hormone as a marker of bone metabolism in chronic k...
Background and objective: Despite the high mortality and morbidity associated with abnormalities in ...
Recent observational studies of patients with stage 3-5 chronic kidney disease (CKD) not undergoing ...
Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of ...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Background: The aim of this study was to determine the disturbances in the levels of mineral in the ...
Objective: Many people who have severe chronic kidney disease (CKD) will eventually develop kidney f...
Background: New bone metabolic markers have become available clinically for evaluating chronic kidne...
BACKGROUND: The management of chronic kidney disease-mineral and bone disorder requires the assessm...
The non-invasive diagnosis of bone turnover in patients with chronic kidney disease (CKD) remains di...
Background and objectives: Clinical management of mineral bone disorder in patients with kidney fail...
Background: Mineral bone disease (MBD) is a systemic disorder of mineral and bone metabolism due to ...
Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders ...
Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). Intern...
Background and objective: Despite the high mortality and morbidity associated with abnormalities in ...
Controversies surrounding the use of Parathyroid hormone as a marker of bone metabolism in chronic k...
Background and objective: Despite the high mortality and morbidity associated with abnormalities in ...
Recent observational studies of patients with stage 3-5 chronic kidney disease (CKD) not undergoing ...
Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of ...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Background: The aim of this study was to determine the disturbances in the levels of mineral in the ...
Objective: Many people who have severe chronic kidney disease (CKD) will eventually develop kidney f...
Background: New bone metabolic markers have become available clinically for evaluating chronic kidne...
BACKGROUND: The management of chronic kidney disease-mineral and bone disorder requires the assessm...